Durgical
EN
Open the app

Antibodies, bispecifics and CAR-T cells: how they work and their emergencies (CRS, ICANS)

  • Treatment and support

New treatments turn the immune system against blood cancers. They can work when chemotherapy fails, but they can set off a dangerous fever storm.

Updated

What it is

Three families use the immune system against blood cancers. Monoclonal antibodies bind a surface marker (CD20 on B cells, CD38 on plasma cells, CD30, CD33, CD22) and kill by recruiting immune cells and complement or by delivering an attached toxin (antibody-drug conjugates). Bispecific T-cell engagers bind CD3 on a T cell and a tumour marker (CD19, BCMA, CD20) at once, linking the two. CAR-T cells are the patient's own T cells, engineered to carry a chimeric antigen receptor against CD19 or BCMA, that multiply in the body. The more T cells are activated, the greater the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

What to know

  • Anti-CD20 (rituximab, obinutuzumab): B-cell lymphomas and CLL; infusion reactions, hepatitis B reactivation, low antibodies and infections.
  • Anti-CD38 (daratumumab): myeloma; it binds the test red cells used in the antibody screen and makes them all look positive, so the blood bank must know before starting.
  • Antibody-drug conjugates: brentuximab vedotin (CD30; nerve damage), gemtuzumab and inotuzumab ozogamicin (CD33 and CD22; liver sinusoidal obstruction).
  • Bispecifics: blinatumomab (CD19 × CD3) for B-cell ALL, teclistamab (BCMA × CD3) for myeloma; CRS and neurotoxicity mostly with the first doses.
  • CAR-T: CD19 for B-cell lymphomas and B-cell ALL (tisagenlecleucel, axicabtagene ciloleucel); BCMA for myeloma.
  • CRS starts with fever, then low blood pressure and low oxygen, usually within days; ICANS causes confusion, word-finding difficulty, changes in handwriting, tremor, seizures and brain swelling, often during or after CRS.

How it is done (and why)

  1. CAR-T: collect the patient's T cells by apheresis; bridging treatment controls the cancer while the cells are made.
  2. The T cells are engineered in a laboratory to express the chimeric receptor and grown in large numbers.
  3. Lymphodepleting chemotherapy (fludarabine and cyclophosphamide) clears space so the CAR-T cells can expand.
  4. Infuse the cells and watch for fever, blood pressure, oxygen and neurological signs several times a day, with a simple writing and naming test.
  5. CRS: grade by fever, hypotension and hypoxia; give tocilizumab (anti-IL-6 receptor) and add steroids if severe, with supportive and ICU care.
  6. ICANS: steroids are the main treatment; seizure prevention and ICU care if severe; tocilizumab alone does not treat it.
  7. Afterwards: the patient stays near the treating centre for weeks, does not drive for a period, and is followed for low counts, infections and low antibodies.

Three ways to point the immune system at a blood cancer

FeatureMonoclonal antibodyBispecific T-cell engagerCAR-T cells
What it isAn antibody (sometimes carrying a toxin) against a tumour markerA molecule binding CD3 on T cells and a tumour markerThe patient's T cells engineered with a new receptor
Who does the killingNatural killer cells, macrophages, complement, or the toxinThe patient's own T cells, linked to the tumourThe engineered T cells, which multiply in the body
How it is givenRepeated infusions or injectionsRepeated infusions or injections, stepped up at firstOne infusion after lymphodepletion
Main early dangerInfusion reactionCRS and neurotoxicity, mostly at the startCRS and ICANS, often severe
Long-term effectB-cell depletion with anti-CD20Low antibodies and infectionsLong B-cell aplasia, low antibodies, prolonged low counts

Risks and precautions

  • Fever after CAR-T or a bispecific may be CRS, but the patient is often neutropenic: take cultures and start antibiotics while treating CRS.
  • ICANS is found early by asking the patient to name objects, write a sentence and count backwards: a decline in handwriting or speech is an early sign.
  • Screen for hepatitis B before anti-CD20 antibodies: reactivation can cause liver failure.
  • Tell the blood bank before daratumumab and give a baseline group and screen: the interference can delay compatible blood.
  • After CD19-directed therapy the B cells are gone for a long time: antibody levels fall and immunoglobulin replacement and infection prophylaxis may be needed.

Monitoring and next step

  • Before treatment: count, kidney and liver tests, hepatitis B, hepatitis C and HIV, group and screen (before anti-CD38), and an immunoglobulin level.
  • After CAR-T or bispecific: daily count, CRP and ferritin, kidney and liver tests, and coagulation; very high ferritin with falling counts suggests an HLH-like syndrome.
  • Fever: blood cultures and a search for infection every time, even when CRS seems obvious.
  • Neurological change: neurological exam and grading score, brain imaging and EEG if severe or seizures are suspected.
  • Months later: immunoglobulin levels, count recovery and response assessment.

Common traps

  • Treating fever after CAR-T as CRS alone: it may be neutropenic sepsis.
  • Relying on tocilizumab for ICANS: it does not cross into the brain well; steroids are the treatment.
  • Forgetting to warn the blood bank before daratumumab: the antibody screen is then unexplained and blood is delayed.
  • Starting rituximab without hepatitis B screening: the screening comes first.
  • Dismissing a small change in handwriting or speech after CAR-T: it can be the first sign of ICANS.

Test yourself

Think of the answer, then tap the question to see it.

Two days after CAR-T infusion a patient has a high fever, then low blood pressure. What is the likely syndrome, and what else must be excluded?

Cytokine release syndrome; infection must be excluded at the same time with cultures and antibiotics, since the patient is often neutropenic.

Why is tocilizumab not enough for a patient with ICANS but no CRS?

It blocks the IL-6 receptor in the blood but does not reach the brain well; steroids are the main treatment for ICANS.

Why does a myeloma patient on daratumumab have a positive antibody screen against every test cell?

Daratumumab binds CD38, which is also on the reagent red cells, so all test cells react; the blood bank uses special methods to find compatible blood.

What is the main difference between a bispecific T-cell engager and a CAR-T cell?

A bispecific is a drug that links the patient's existing T cells to the tumour and must be given repeatedly; CAR-T cells are engineered T cells given once that multiply.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers (National Cancer Institute (NIH), 2024); Monoclonal Antibodies (National Cancer Institute (NCI), 2026); Blinatumomab Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2024); Teclistamab-cqyv Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.